[go: up one dir, main page]

WO2003034028A3 - Methods for identifying and using modulators of estrogen related receptor gamma - Google Patents

Methods for identifying and using modulators of estrogen related receptor gamma Download PDF

Info

Publication number
WO2003034028A3
WO2003034028A3 PCT/US2002/032917 US0232917W WO03034028A3 WO 2003034028 A3 WO2003034028 A3 WO 2003034028A3 US 0232917 W US0232917 W US 0232917W WO 03034028 A3 WO03034028 A3 WO 03034028A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying
modulators
receptor gamma
related receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/032917
Other languages
French (fr)
Other versions
WO2003034028A2 (en
Inventor
Steven G Blanchard
Aaron Bayne Miller
Lisa A Orband-Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2002342058A priority Critical patent/AU2002342058A1/en
Priority to US10/491,677 priority patent/US20050074765A1/en
Priority to JP2003536715A priority patent/JP2005509628A/en
Priority to EP02776223A priority patent/EP1436395A4/en
Publication of WO2003034028A2 publication Critical patent/WO2003034028A2/en
Publication of WO2003034028A3 publication Critical patent/WO2003034028A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/362—Menopause

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods of identifying compounds that interact with ERRy and are useful in the treatment of ERRy- and ER-mediated diseases, risk factors, and conditions are provided. Pharmaceutical compositions containing compounds that interact directly with ERRy and methods of using these compositions in the treatment of ERRy- and ER-mediated diseases, risk factors, and conditions are also provided.
PCT/US2002/032917 2001-10-16 2002-10-16 Methods for identifying and using modulators of estrogen related receptor gamma Ceased WO2003034028A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002342058A AU2002342058A1 (en) 2001-10-16 2002-10-16 Methods for identifying and using modulators of estrogen related receptor gamma
US10/491,677 US20050074765A1 (en) 2002-10-16 2002-10-16 Methods for identifying and using modulators of estrogen related receptor gamma
JP2003536715A JP2005509628A (en) 2001-10-16 2002-10-16 Methods of identifying and using modulators of estrogen-related receptor gamma
EP02776223A EP1436395A4 (en) 2001-10-16 2002-10-16 Methods for identifying and using modulators of estrogen related receptor gamma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32988801P 2001-10-16 2001-10-16
US60/329,888 2001-10-16

Publications (2)

Publication Number Publication Date
WO2003034028A2 WO2003034028A2 (en) 2003-04-24
WO2003034028A3 true WO2003034028A3 (en) 2004-02-19

Family

ID=23287445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032917 Ceased WO2003034028A2 (en) 2001-10-16 2002-10-16 Methods for identifying and using modulators of estrogen related receptor gamma

Country Status (4)

Country Link
EP (1) EP1436395A4 (en)
JP (1) JP2005509628A (en)
AU (1) AU2002342058A1 (en)
WO (1) WO2003034028A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655756B2 (en) 2005-05-27 2010-02-02 Johnson & Johnson Pharmaceutical Research & Development, Llc Crystallized structure of estrogen related receptor gamma in complex with bisphenol A
KR101631581B1 (en) * 2010-06-11 2016-06-17 한국생명공학연구원 FRET sensor fused nano-particles and detecting method for phytoestrogen using the same
KR101579008B1 (en) * 2013-09-25 2015-12-22 경북대학교 산학협력단 Pharmaceutical compositions for the prevention or treatment of retinopathy, including ERR-y inhibitors, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096301A (en) * 1986-10-10 2000-08-01 Industria Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096301A (en) * 1986-10-10 2000-08-01 Industria Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COWARD P. ET AL.: "4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 15, 17 July 2001 (2001-07-17), pages 8880 - 8884, XP002971442 *
ROLLEROVA E. ET AL.: "Intracellular estrogen receptors, their characterization and function", ENDOCR. REGUL., vol. 34, 2000, pages 203 - 218, XP002971443 *
See also references of EP1436395A4 *

Also Published As

Publication number Publication date
EP1436395A4 (en) 2006-12-13
AU2002342058A1 (en) 2003-04-28
JP2005509628A (en) 2005-04-14
WO2003034028A2 (en) 2003-04-24
EP1436395A2 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
AU2002325329A1 (en) Device for distributing substances
TWI340738B (en) Modulators of the glucocorticoid receptor
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
AU2002338454A1 (en) Permission based marketing for use with medical prescriptions
WO2002099054A3 (en) Hccss as modifiers of the p53 pathway and methods of use
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2003251970A1 (en) Modulators of the glucocorticoid receptor and method
AP2003002907A0 (en) Liquid pharmaceutical composition.
IL172512A0 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
AU2003298611A1 (en) Mixed lineage kinase modulators
AU2001256373A1 (en) Syringe and method for the use thereof
AU2001284471A1 (en) Compositions for improving mental concentration
TWI319762B (en) 1,7,8-trifluoro-2-naphthol and manufacturing methods for liquid crystal compositions containing the same
AU6565100A (en) Liquid pharmaceutical composition based on paracetamol
AU2002316723A1 (en) Ocular ionthophoretic device and method for using the same
WO2003034028A3 (en) Methods for identifying and using modulators of estrogen related receptor gamma
AU2003252493A1 (en) Pharmaceutical composition containing decoy and method of using the same
AU2003237273A1 (en) Methods and apparatus for mixing and distributing fluids
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002255354A1 (en) Minoxidil-containing liquid composition
AU2003220966A1 (en) Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
AU2003261986A1 (en) Device for liquid dilution and mixing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10491677

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003536715

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002776223

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002776223

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002776223

Country of ref document: EP